Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

PRIMARY OBJECTIVES:

I. To investigate the genomic (transcriptional profiles) and proteomic (pathway activation)
features that distinguish tumors that do not achieve a pathologic complete response (pCR)
after neoadjuvant systemic therapy (NST) and correlate these features with outcome in the
presence and absence of adjuvant ixabepilone.

II. To evaluate the presence of circulating tumor cells (CTCs) at baseline (before
chemotherapy starts; if radiation is used, after radiation ends), during and after
ixabepilone therapy or during observation.

SECONDARY OBJECTIVES:

I. To collect serial blood samples for future pharmacogenomic studies. II. To determine if
the addition of adjuvant ixabepilone will improve recurrence-free survival in patients that
have significant residual HER 2/neu-negative breast cancer after NST.

III. To assess the toxicity of adjuvant ixabepilone in this group of patients.

OUTLINE: Participants are randomized to 1 of 2 groups.

GROUP I (IXABEPILONE): Participants receive ixabepilone intravenously (IV) over 3 hours on
day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity.

GROUP II (STANDARD OF CARE): Participants receive standard of care for 18 weeks.

After completion of study treatment, participants are followed up every 3 months for 2 years
and every 6 months for 3 years.

Inclusion Criteria:

- Patients with histologic confirmation of invasive HER2/neu-negative breast cancer
(immunohistochemistry [IHC] 0-1+ or fluorescence in situ hybridization
[FISH]-negative) that have received complete anthracycline and taxane neoadjuvant
systemic therapy and that at the time of surgery are expected to have significant
residual disease. Therapy should include at least 4 cycles of an anthracycline-based
regimen (adriamycin-cytoxan [AC], 5-fluorouracil/adriamycin/intravenous [IV]
cyclophosphamide [FAC], fluorouracil-epirubicin-IV cytoxan [FEC]) and 12 weeks of a
taxane-based regimen (weekly paclitaxel, every 3-week docetaxel).

- Patients who did not complete therapy due to disease progression are eligible.

- Patients with bilateral breast cancers are eligible.

- Patients should have a Karnofsky performance scale of >= 70%.

- Peripheral granulocyte count of >= 1500/mm^3.

- Platelet count >= 100000 mm^3.

- Bilirubin within normal laboratory values.

- Alkaline phosphatase may be up to 1.5 x upper limit of normal (ULN) of the
institution.

- Transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST])
may be up to 1.5 x upper limit of normal (ULN) of the institution.

- Creatinine levels within normal range.

- Negative serum pregnancy test for a woman of childbearing potential.

- Women of childbearing potential (WOCP) must use a reliable and appropriate
contraceptive method during the study and 6 months after chemotherapy is completed.
Women of childbearing potential (WOCBP) are women who are not menopausal for 12 months
or had no previous surgical sterilization.

- Patients must agree to have study tissue collections and blood sample collections.

- Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study, in keeping with institutional policy.

- Patients should have their surgical tissues evaluated for residual cancer burden (RCB)
and be used for correlative studies.

- Sexually active women of childbearing potential must use an effective method of birth
control during the course of the study, in a manner such that risk of failure is
minimized. Prior to study enrollment, women of childbearing potential (WOCBP) must be
advised of the importance of avoiding pregnancy during trial participation and the
potential risk factors for an unintentional pregnancy. In addition, men enrolled on
this study should understand the risks to any sexual partner of childbearing potential
and should practice an effective method of birth control.

- All WOCBP MUST have a negative pregnancy test within 7 days prior to first receiving
investigational product. If the pregnancy test is positive, the patient must not
receive investigational product and must not be enrolled in the study. In addition,
all WOCBP will be instructed to contact the Investigator immediately if they suspect
they might be pregnant (e.g., missed or late menstrual period) at any time during
study participation. The principal investigator (PI) will immediately notify BMS in
the event of a confirmed pregnancy in a patient participating in the study.

Exclusion Criteria:

- Patients whose tumors express HER2 protein or have HER2/neu gene amplification.

- Patients with a history of other invasive malignancies diagnosed and treated within
the previous 5 years, except non-melanoma skin cancer and non-invasive cervical
cancer.

- Other concurrent severe and/or uncontrolled medical disease which could compromise
participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension,
severe infection, severe malnutrition, unstable angina, or congestive heart failure -
New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic
heart disease, myocardial infarction within six months, chronic liver or renal
disease, active upper gastrointestinal [GI] tract ulceration).

- Patients with a pre-existing peripheral neuropathy > grade 1.

- Evidence of distant metastases.